IP Library › Granted Patent US 12,344,710
Granted Patent B2
US 12,344,710 · App. 16/987,913 · Granted Jul 1, 2025

Semi-crystalline copolyamides, moulding compounds comprising same and their use, and mouldings manufactured from same

Inventors: Philipp Harder (Chur, CH); Christian Schubert (Domat/Ems, CH); Ronny Ebling (Domat/Ems, CH)
Assignee: EMS-Patent AG
C08G69/265C08K7/14C08G2250/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,344,710
App. No.
16/987,913
Granted
Jul 1, 2025
Kind
B2
Abstract

The present invention relates to semi-crystalline copolyamides and to moulding compounds manufactured from same that contain at least one filler, and optionally additives in addition to the semi-crystalline copolyamide. The invention equally relates to mouldings manufactured from same.

Claims (64)

1. A semi-crystalline copolyamide formed from the following monomers (a1) to (a5):

(a1) 23 to 37.5 mol % 1,6-hexanediamine;

(a2) 12.5 to 22 mol % 1,3-bis(aminomethyl)cyclohexane;

(a3) 0 to 5 mol % at least one diamine selected from the group consisting of ethylenediamine, butanediamine, pentanediamine, methylpentanediamine, 1,8-octanediamine, methyloctanediamine, 1,9-nonanediamine, 1,10-decanediamine, 1,11-undecanediamine, 1,12-dodecaneamine, trimethyl hexamethylenediamine, m-xylylenediamine, and p-xylylenediamine;

(a4) 45 to 50 mol % 1,6-hexanedioic acid; and

(a5) 0 to 5 mol % at least one dicarboxylic acid with 2 to 44 carbon atoms, differing from monomer (a4);

wherein the proportions of the monomers (a1), (a2), and (a3) are with respect to the sum of the diamines utilized and add up to 50 mol %;

wherein the proportions of the monomers (a4) and (a5) are with respect to the sum of the dicarboxylic acids utilized and add up to 50 mol %;

wherein the monomers (a1) to (a5) add up to 100 mol %;

wherein the copolyamide has a melting temperature in the range from 180 to 235° C.; and

when the semi-crystalline copolyamide is combined with a filler to form a moulding compound, the resulting moulding compound would have a modulus of elasticity in accordance with ISO 527 of at least 5000 MPa.

2. The copolyamide in accordance with claim 1 , wherein:

the proportion of monomer (a1) in the copolyamide is in the range from 23 to 35 mol-%; and/or

the proportion of monomer (a2) in the copolyamide is in the range from 14 to 22 mol %; and/or

the proportion of monomer (a3) in the copolyamide is in the range from 0 to 2.5 mol-%;

wherein the proportions of the monomers (a1), (a2), and (a3) are with respect to the sum of the diamines used and add up to 50 mol %.

3. The copolyamide in accordance with claim 2 , wherein:

the proportion of monomer (a1) in the copolyamide is in the range from 25 to 32.5 mol %, and/or

the proportion of monomer (a2) in the copolyamide is in the range from 16 to 20 mol %.

4. The copolyamide in accordance with claim 1 , wherein:

the proportion of monomer (a4) in the copolyamide is in the range from 47.5 to 50 mol %; and/or

the proportion of monomer (a5) in the copolyamide is in the range from 0 to 2.5 mol-%,

wherein the proportions of monomers (a4) and (a5) are with respect to the sum of the dicarboxylic acids utilized and add up to 50 mol %.

5. The copolyamide in accordance with claim 1 , wherein:

the at least one monomer (a5) is selected from the group consisting of isophthalic acid, terephthalic acid, naphthalene dicarboxylic acid, 1,9-nonanedioic acid, 1,10-decanedioic acid, 1,11-undecanedioic acid, 1,12-dodecanedioic acid, 1,13-tridecanedioic acid, 1,14-tetradecanedioic acid, 1,15-pentadecanoic acid, 1,16-hexadecanedioic acid, 1,17-heptadecanedioic acid, 1,18-octadecanedioic acid, arachidic acid, Japan acid, behenic acid, cyclohexanedioic acid, phenylindanedicarboxylic acid, phenylenediooxydiacetic acid, and dimer fatty acid with 35 or 44 carbon atoms.

6. The copolyamide in accordance with claim 1 , wherein the copolyamide has a relative viscosity, measured with 0.5 g in 100 ml m-cresol at 20° C., of 1.45 to 2.10.

7. The copolyamide in accordance with claim 6 , wherein the copolyamide has a relative viscosity, measured with 0.5 g in 100 ml m-cresol at 20° C., of 1.50 to 2.05.

8. The copolyamide in accordance with claim 1 , wherein the copolyamide has at least one of the following properties:

a glass transition temperature in the range from 50 to 200° C.,

a crystallization temperature in the range from 130 to 200° C., and

a crystallization rate in the range from 12 to 50 J/g min.

9. A polyamide moulding compound comprising a copolyamide formed from the following monomers (a1) to (a5):

(a1) 23 to 37.5 mol % 1,6-hexanediamine;

(a2) 12.5 to 22 mol % 1,3-bis(aminomethyl)cyclohexane;

(a3) 0 to 2.5 mol % at least one diamine with 2 to 35 carbon atoms, differing from monomers (a1) and (a2);

(a4) 45 to 50 mol % 1,6-hexanedioic acid; and

(a5) 0 to 5 mol % at least one dicarboxylic acid with 2 to 44 carbon atoms, differing from monomer (a4);

wherein the proportions of the monomers (a1), (a2), and (a3) are with respect to the sum of the diamines utilized and add up to 50 mol %;

wherein the proportions of the monomers (a4) and (a5) are with respect to the sum of the dicarboxylic acids utilized and add up to 50 mol %;

wherein the monomers (a1) to (a5) add up to 100 mol %; and

wherein the copolyamide has a melting temperature in the range from 180 to 235° C.;

and a filler.

10. A polyamide moulding material consisting of

(i) 22 to 70 wt % of at least one copolyamide in accordance with claim 1 ;

(ii) 30 to 70% by weight of at least one filler; and

(iii) 0 to 8 wt % of at least one additive,

wherein component (iii) differs from component (ii), and wherein the proportion of components (i) to (iii) add up to 100 wt %.

11. The polyamide moulding material in accordance with claim 10 , wherein a moulding manufactured from the polyamide moulding material has at least one of the following properties:

a modulus of elasticity determined in accordance with ISO 527 of at least 5000 MPa, and/or

a gloss value of 70 to 100 GU determined in accordance with DIN EN 2813 (2015) in the dry state at 60°; and/or

a gloss value of 60 to 100 GU determined in accordance with DIN EN 2813 (2015) in the conditioned state at 60°.

12. A moulding produced from the copolyamide of claim 1 .

13. A moulding produced from a polyamide moulding material in accordance with claim 10 .

14. The moulding in accordance with claim 13 , wherein the moulding is selected from the group consisting of non-lacquered visible parts with or without a function, car passenger compartment or trunk parts, household parts, mechanical engineering parts, parts of electrical devices, parts of electronic devices, parts of domestic appliances, and parts of furniture.

15. A semi-crystalline copolyamide formed from the following monomers (a1), (a2), (a4), and (a5):

(a1) 23 to 37.5 mol % 1,6-hexanediamine;

(a2) 12.5 to 22 mol % 1,3-bis(aminomethyl)cyclohexane;

(a4) 45 to 50 mol % 1,6-hexanedioic acid; and

(a5) 0 to 5 mol % at least one dicarboxylic acid with 2 to 44 carbon atoms, differing from monomer (a4);

wherein the proportions of the monomers (a1) and (a2) are with respect to the sum of the diamines utilized and add up to 50 mol %;

wherein the proportion of monomer (a4), and of monomer (a5) if present, are with respect to the sum of the dicarboxylic acids utilized and add up to 50 mol %; and

wherein the monomers (a1), (a2), and (a4), and (a5) if present, add up to 100 mol %; and

wherein the copolyamide has a melting temperature in the range from 180 to 235° C.; and

when the semi-crystalline copolyamide is combined with a filler to form a moulding compound, the resulting moulding compound would have a modulus of elasticity in accordance with ISO 527 of at least 5000 MPa.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 1, 2020
From: HARDER, PHILIPP; SCHUBERT, CHRISTIAN; EBLING, RONNY
To: EMS-PATENT AG
Reel/Frame 053661/0539 →
Priority Claims (1)
EP 19191021 · Aug 9, 2019 · regional
Continuity (1)
Related Publication 20210040264A1 · Feb 11, 2021
References Cited (168)
US 3012994A · Bell · 1961 [cited by examiner]
US 6482889B1 · Kurz · 2002 [cited by applicant]
US 7723411B2 · Schneider · 2010 [cited by applicant]
US 7973191B2 · Doring et al. · 2011 [cited by applicant]
US 8022170B2 · Hoffman et al. · 2011 [cited by applicant]
US 8268956B2 · Bühler et al. · 2012 [cited by applicant]
US 8383244B2 · Bayer et al. · 2013 [cited by applicant]
US 8404323B2 · Pfleghar et al. · 2013 [cited by applicant]
US 8586662B2 · Harder et al. · 2013 [cited by applicant]
US 8604120B2 · Stöppelmann et al. · 2013 [cited by applicant]
US 8993662B2 · Kaplan · 2015 [cited by applicant]
US 9109115B2 · Buhler et al. · 2015 [cited by applicant]
US 9133322B2 · Roth et al. · 2015 [cited by applicant]
US 9359532B2 · Kaplan · 2016 [cited by applicant]
US 9453106B2 · Buhler et al. · 2016 [cited by applicant]
US 9644081B2 · Aepli et al. · 2017 [cited by applicant]
US 9663655B2 · Aepli · 2017 [cited by applicant]
US 9815967B2 · Harder et al. · 2017 [cited by applicant]
US 9963547B2 · Hoppe et al. · 2018 [cited by applicant]
US 9963591B2 · Bayer et al. · 2018 [cited by applicant]
US 9969882B2 · Thomas et al. · 2018 [cited by applicant]
US 10005268B2 · Jeltsch et al. · 2018 [cited by applicant]
US 10047054B2 · Kaplan · 2018 [cited by applicant]
US 10144805B2 · Bayer et al. · 2018 [cited by applicant]
US 10233326B2 · Koch et al. · 2019 [cited by applicant]
US 10544286B2 · Nakano et al. · 2020 [cited by applicant]
US 10577478B2 · Fujii et al. · 2020 [cited by applicant]
US 10683418B2 · Thomas et al. · 2020 [cited by applicant]
US 10717816B2 · Aepli et al. · 2020 [cited by applicant]
US 10751961B2 · Cheung · 2020 [cited by applicant]
US 10767047B2 · Aepli et al. · 2020 [cited by applicant]
US 10767048B2 · Aepli et al. · 2020 [cited by applicant]
US 10836905B2 · Wiedemann et al. · 2020 [cited by applicant]
US 10843389B2 · Weis et al. · 2020 [cited by applicant]
US 10882975B2 · Stöppelmann · 2021 [cited by applicant]
US 10889713B2 · Schubert et al. · 2021 [cited by applicant]
US 10899527B2 · Sütterlin et al. · 2021 [cited by applicant]
US 20040030023A1 · Buhler · 2004 [cited by examiner]
US 20060235190A1 · Hoffman et al. · 2006 [cited by applicant]
US 20060264542A1 · Schneider · 2006 [cited by applicant]
US 20080135720A1 · Bühler et al. · 2008 [cited by applicant]
US 20080300347A1 · Kurz et al. · 2008 [cited by applicant]
US 20100069657A1 · Doring et al. · 2010 [cited by applicant]
US 20100168423A1 · Doring et al. · 2010 [cited by applicant]
US 20100279111A1 · Harder et al. · 2010 [cited by applicant]
US 20110220667A1 · Pfleghar et al. · 2011 [cited by applicant]
US 20120029133A1 · Stöppelmann et al. · 2012 [cited by applicant]
US 20120115993A1 · Kaplan · 2012 [cited by applicant]
US 20120237708A1 · Caviezel et al. · 2012 [cited by applicant]
US 20120321829A1 · Bayer et al. · 2012 [cited by applicant]
US 20130136911A1 · Bender et al. · 2013 [cited by applicant]
US 20130317168A1 · Buhler et al. · 2013 [cited by applicant]
US 20140094548A1 · Roth et al. · 2014 [cited by applicant]
US 20140135458A1 · Kaplan · 2014 [cited by applicant]
US 20140171573A1 · Bayer et al. · 2014 [cited by applicant]
US 20140272227A1 · Jeltsch et al. · 2014 [cited by applicant]
US 20140275392A1 · Buhler et al. · 2014 [cited by applicant]
US 20150051343A1 · Kaplan · 2015 [cited by applicant]
US 20150104638A1 · Jeltsch et al. · 2015 [cited by applicant]
US 20150126635A1 · Liedloff et al. · 2015 [cited by applicant]
US 20150126701A1 · Liedloff et al. · 2015 [cited by applicant]
US 20150218374A1 · Thomas et al. · 2015 [cited by applicant]
US 20150284531A1 · Aepli et al. · 2015 [cited by applicant]
US 20150291795A1 · Aepli · 2015 [cited by applicant]
US 20150352765A1 · Hoffmann et al. · 2015 [cited by applicant]
US 20150368398A1 · Hoppe et al. · 2015 [cited by applicant]
US 20160130439A1 · Koch et al. · 2016 [cited by applicant]
US 20160280914A1 · Thomas et al. · 2016 [cited by applicant]
US 20160297123A1 · Weis et al. · 2016 [cited by applicant]
US 20160376423A1 · Harder et al. · 2016 [cited by applicant]
US 20170058123A1 · Sütterlin et al. · 2017 [cited by applicant]
US 20170107326A1 · Bayer et al. · 2017 [cited by applicant]
US 20170137608A1 · Stöppelmann · 2017 [cited by applicant]
US 20170137609A1 · Stöppelmann · 2017 [cited by applicant]
US 20170183140A1 · Sütterlin et al. · 2017 [cited by applicant]
US 20170225414A1 · Cheung · 2017 [cited by applicant]
US 20180022900A1 · Nakano et al. · 2018 [cited by applicant]
US 20180100064A1 · Aepli et al. · 2018 [cited by applicant]
US 20180112059A1 · Fujii et al. · 2018 [cited by applicant]
US 20180155545A1 · Stöppelmann et al. · 2018 [cited by applicant]
US 20180171141A1 · Thomas et al. · 2018 [cited by applicant]
US 20180251600A1 · Hoffmann et al. · 2018 [cited by applicant]
US 20180298191A1 · Schubert et al. · 2018 [cited by applicant]
US 20190055356A1 · Aepli et al. · 2019 [cited by applicant]
US 20190055404A1 · Aepli et al. · 2019 [cited by applicant]
US 20190055405A1 · Aepli et al. · 2019 [cited by applicant]
US 20190062554A1 · Wiedemann et al. · 2019 [cited by applicant]
US 20190136053A1 · Fujii et al. · 2019 [cited by applicant]
US 20200024415A1 · Holzschuh et al. · 2020 [cited by applicant]
US 20200024416A1 · Holzschuh et al. · 2020 [cited by applicant]
US 20200109284A1 · Wiedemann · 2020 [cited by applicant]
US 20200198203A1 · Cavieze · 2020 [cited by applicant]
EP 3309199A1 · 2018 [cited by applicant]
EP 3392290A1 · 2018 [cited by applicant]
GB 0922677A · 1963 [cited by applicant]
GB 1433144A · 1976 [cited by applicant]
GB 2351898A · 2001 [cited by applicant]
JP 49055796A · 1974 [cited by applicant]
JP 2018062651A · 2018 [cited by applicant]
JP 2018178117A · 2018 [cited by applicant]
KR 20030066669A · 2003 [cited by applicant]
US 10,875,999 B2, 12/2020, Stöppelmann et al. (withdrawn) [cited by applicant]
U.S. Appl. No. 09/533,280, filed Mar. 22, 2000. [cited by applicant]
U.S. Appl. No. 10/536,494, filed May 24, 2005. [cited by applicant]
U.S. Appl. No. 10/553,259, filed Oct. 11, 2005. [cited by applicant]
U.S. Appl. No. 11/950,964, filed Dec. 5, 2007. [cited by applicant]
U.S. Appl. No. 12/091,024, filed Apr. 21, 2008. [cited by applicant]
U.S. Appl. No. 12/539,972, filed Aug. 12, 2009. [cited by applicant]
U.S. Appl. No. 12/540,007, filed Aug. 12, 2009. [cited by applicant]
U.S. Appl. No. 12/743,097, filed May 14, 2010. [cited by applicant]
U.S. Appl. No. 13/045,682, filed Mar. 11, 2011. [cited by applicant]
U.S. Appl. No. 13/186,785, filed Jul. 20, 2011. [cited by applicant]
U.S. Appl. No. 13/290,718, filed Nov. 7, 2011. [cited by applicant]
U.S. Appl. No. 13/421,541, filed Mar. 15, 2012. [cited by applicant]
U.S. Appl. No. 13/481,451, filed May 25, 2012. [cited by applicant]
U.S. Appl. No. 13/674,395, filed Nov. 12, 2012. [cited by applicant]
U.S. Appl. No. 13/800,102, filed Mar. 13, 2013. [cited by applicant]
U.S. Appl. No. 13/898,099, filed May 20, 2013. [cited by applicant]
U.S. Appl. No. 13/971,376, filed Aug. 20, 2013. [cited by applicant]
U.S. Appl. No. 14/078,134, filed Nov. 12, 2013. [cited by applicant]
U.S. Appl. No. 14/204,404, filed Mar. 11, 2014. [cited by applicant]
U.S. Appl. No. 14/205,667, filed Mar. 12, 2014. [cited by applicant]
U.S. Appl. No. 14/221,930, filed Mar. 21, 2014. [cited by applicant]
U.S. Appl. No. 14/397,529, filed Oct. 28, 2014. [cited by applicant]
U.S. Appl. No. 14/397,534, filed Oct. 28, 2014. [cited by applicant]
U.S. Appl. No. 14/504,651, filed Oct. 2, 2014. [cited by applicant]
U.S. Appl. No. 14/607,676, filed Jan. 28, 2015. [cited by applicant]
U.S. Appl. No. 14/663,105, filed Mar. 19, 2015. [cited by applicant]
U.S. Appl. No. 14/681,669, filed Apr. 8, 2015. [cited by applicant]
U.S. Appl. No. 14/729,277, filed Jun. 3, 2015. [cited by applicant]
U.S. Appl. No. 14/740,736, filed Jun. 16, 2015. [cited by applicant]
U.S. Appl. No. 14/915,031, filed Feb. 26, 2016. [cited by applicant]
U.S. Appl. No. 14/935,642, filed Nov. 9, 2015. [cited by applicant]
U.S. Appl. No. 15/090,881, filed Apr. 5, 2016. [cited by applicant]
U.S. Appl. No. 15/105,011, filed Sep. 6, 2016. [cited by applicant]
U.S. Appl. No. 15/253,506, filed Aug. 31, 2016. [cited by applicant]
U.S. Appl. No. 15/285,947, filed Oct. 5, 2016. [cited by applicant]
U.S. Appl. No. 15/349,636, filed Nov. 11, 2016. [cited by applicant]
U.S. Appl. No. 15/349,729, filed Nov. 11, 2016. [cited by applicant]
U.S. Appl. No. 15/385,432, filed Dec. 20, 2016. [cited by applicant]
U.S. Appl. No. 15/385,519, filed Dec. 20, 2016. [cited by applicant]
U.S. Appl. No. 15/546,373, filed Jul. 26, 2017. [cited by applicant]
U.S. Appl. No. 15/729,321, filed Oct. 10, 2017. [cited by applicant]
U.S. Appl. No. 15/789,069, filed Oct. 20, 2017. [cited by applicant]
U.S. Appl. No. 15/826,177, filed Nov. 29, 2017. [cited by applicant]
U.S. Appl. No. 15/895,537, filed Feb. 13, 2018. [cited by applicant]
U.S. Appl. No. 15/910,891, filed Mar. 2, 2018. [cited by applicant]
U.S. Appl. No. 15/955,737, filed Apr. 18, 2018. [cited by applicant]
U.S. Appl. No. 16/094,198, filed Oct. 16, 2018. [cited by applicant]
U.S. Appl. No. 16/104,028, filed Aug. 16, 2018. [cited by applicant]
U.S. Appl. No. 16/104,035, filed Aug. 16, 2018. [cited by applicant]
U.S. Appl. No. 16/104,043, filed Aug. 16, 2018. [cited by applicant]
U.S. Appl. No. 16/115,055, filed Aug. 28, 2018. [cited by applicant]
U.S. Appl. No. 16/515,119, filed Jul. 18, 2019. [cited by applicant]
U.S. Appl. No. 16/515,151, filed Jul. 18, 2019. [cited by applicant]
U.S. Appl. No. 16/595,559, filed Oct. 8, 2019. [cited by applicant]
U.S. Appl. No. 16/717,369, filed Dec. 17, 2019. [cited by applicant]
U.S. Appl. No. 16/956,564, filed Jun. 20, 2020. [cited by applicant]
U.S. Appl. No. 16/956,576, filed Jun. 20, 2020. [cited by applicant]
U.S. Appl. No. 16/956,579, filed Jun. 20, 2020. [cited by applicant]
U.S. Appl. No. 16/956,580, filed Jun. 20, 2020. [cited by applicant]
U.S. Appl. No. 16/988,011, filed Aug. 7, 2020. [cited by applicant]
U.S. Appl. No. 17/129,507, filed Dec. 21, 2020. [cited by applicant]
U.S. Appl. No. 17/129,606, filed Dec. 21, 2020. [cited by applicant]
European Patent Office, Extended European Search Report in European Patent Application No. 19 191 021.5 (Feb. 4, 2020). [cited by applicant]
China National Intellectual Property Administration, First Office Action in Chinese Patent Application No. 2020107944796 (Mar. 31, 2023). [cited by applicant]
Japan Patent Office, Notification of Reasons for Refusal in Japanese Patent Application No. 2020-132942 (Jul. 30, 2024). [cited by applicant]
Korean Intellectual Property Office, Notice of Reasons for Rejection in Korean Patent Application No. 10-2020-0099084 (May 16, 2025). [cited by applicant]